ArticleEuropean archives of psychiatry and clinical neuroscience2025
Decoding Huntington's disease: a global survey on symptoms and genetic testing practices.
Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism.Current neurology and neuroscience reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuntington's disease (HD) is a fatal, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene. While chorea is the hallmark motor symptom, HD presents with diverse psychiatric and cognitive manifestations that usually precede motor onset.
methodsA 10-question online survey was distributed to 130 neurologists and neuro-geneticists from the European Huntington's Disease Network (EHDN) to identify clinical symptoms considered pathognonomic of HD and criteria for genetic testing. Responses from 52 specialists were anonymized and analysed using Microsoft Excel and SPSS 26.
resultsRespondents, averaging 18.4 years of experience, universally identified chorea as indicative of HD, alongside cognitive slowing, irritability, and gait abnormalities. Symptoms like neuropathy, limb weakness, and tremor were deemed inconsistent with HD. Notably, 19% of experts reported that ancillary symptoms would not deter them from recommending testing if a primary HD symptom was present. Without a family history, only chorea with or without additional symptoms was deemed sufficient for testing. DISCUSSION: The findings highlight the complexity of diagnosing HD, the importance of considering subtle psychiatric and cognitive symptoms, and the need for comprehensive patient counselling. Advances in genetic testing and therapeutic trials targeting the molecular root of HD offer hope for curative treatments.
conclusionThis study underscores the growing recognition of HD's pleiotropy, the ethical considerations in testing, and the importance of clinical vigilance as patients may often first present in a non-neurological setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.